Top Markets
#1 0G 0G +46.62%
#2 Merlin's Seal BTC Merlin's Seal BTC +42.87%
#3 StonkBroker StonkBroker +34.38%
#4 Useless Coin Useless Coin +29.03%
#5 SAFEcoin SAFEcoin +27.94%
#6 Pons Pons +24.13%
#7 Dogs Dogs +22.45%
#8 rsERG rsERG +21.90%
#9 Zora Zora +20.60%
#10 Verus Coin Verus Coin +19.31%
Coin of the day
0G 0G
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Impact Therap-b Impact Therap-b

Impact Therap-b

7630
Rang in Aktien #13196
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and... IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Aktienkurs
$1.85
Marktkapitalisierung
$510.85M
Veränderung (1 Tag)
-7.37%
Veränderung (1 Jahr)
-
Land
CN
Handel Impact Therap-b (7630)

Kategorie

Healthcare
EPS für Impact Therap-b (7630)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Impact Therap-b beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Impact Therap-b von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $29.85 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $8.65 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $3.55 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $20.39 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $1.26 -
US